BELLUS Health (BLU) Gets a Buy Rating from RBC Capital
RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU) on February 25 and set a price target of $8.00. The company’s shares closed last Friday at $3.82.
According to TipRanks.com, Renza is a 4-star analyst with an average return of 16.9% and a 49.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Aprea Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $8.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.03 and a one-year low of $2.01. Currently, BELLUS Health has an average volume of 1.56M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More on BLU: